Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.
暂无分享,去创建一个
E. Laws | D. Schiff | M. Vance | J. Jane | M. Thorner | E. Laws | M. Lopes | T. Cunningham | J. Longtine | J. Jane | Zachary M. Bush | M. Lopes
[1] J. Bruce,et al. Temozolomide (Temodar®) and capecitabine (Xeloda®) treatment of an aggressive corticotroph pituitary tumor , 2011, Pituitary.
[2] C. Sommer,et al. MGMT activity, promoter methylation and immunohistochemistry of pretreatment and recurrent malignant gliomas: a comparative study on astrocytoma and glioblastoma , 2010, International journal of cancer.
[3] B. Scheithauer,et al. O‐Methylguanine‐DNA Methyltransferase Immunoexpression in a Double Pituitary Adenoma: Case Report , 2010, Neurosurgery.
[4] Diana Cheng,et al. Development of a validation algorithm for 'present on admission' flagging , 2009, BMC Medical Informatics Decis. Mak..
[5] M. Andersen,et al. Temozolomide treatment of a pituitary carcinoma and two pituitary macroadenomas resistant to conventional therapy. , 2009, European journal of endocrinology.
[6] S. Clark,et al. Low O6‐methylguanine‐DNA methyltransferase (MGMT) expression and response to temozolomide in aggressive pituitary tumours , 2009, Clinical endocrinology.
[7] A. Chiò,et al. MGMT promoter hypermethylation in a series of 104 glioblastomas. , 2009, Cancer genomics & proteomics.
[8] M. Buchfelder,et al. Pituitary tumor size in acromegaly during pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. , 2009, European journal of endocrinology.
[9] C. Marosi,et al. O6‐methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas , 2009, Cancer.
[10] H. Heinzl,et al. Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker * , 2008, Brain pathology.
[11] A. Tischler,et al. Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists , 2007, Pituitary.
[12] M. Weller,et al. Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine , 2007, Oncogene.
[13] C. Stratakis,et al. The effects of SOM230 on cell proliferation and adrenocorticotropin secretion in human corticotroph pituitary adenomas. , 2006, The Journal of clinical endocrinology and metabolism.
[14] C. Eskey,et al. Long-term response of pituitary carcinoma to temozolomide. Report of two cases. , 2006, Journal of neurosurgery.
[15] Yueping Shen,et al. Aberrant Promoter Methylation of p16INK4a and O6‐Methylguanine‐DNA Methyltransferase Genes in Workers at a Chinese Uranium Mine , 2006, Journal of occupational health.
[16] H. Shahinian,et al. Temozolomide: a novel treatment for pituitary carcinoma. , 2006, The Lancet. Oncology.
[17] C. Mothersill,et al. Radiation-induced genomic instability is associated with DNA methylation changes in cultured human keratinocytes. , 2006, Mutation research.
[18] E. Rutgers,et al. European organisation for research and treatment of cancer (EORTC) 10981–22023 after mapping of the axilla radiotherapy or surgery (AMAROS) trial update , 2006 .
[19] O. Kovalchuk,et al. Stable loss of global DNA methylation in the radiation-target tissue--a possible mechanism contributing to radiation carcinogenesis? , 2005, Biochemical and biophysical research communications.
[20] Justus J. Randolph. Free-Marginal Multirater Kappa (multirater K[free]): An Alternative to Fleiss' Fixed-Marginal Multirater Kappa. , 2005 .
[21] B. Scheithauer,et al. Pituitary carcinoma , 2005, Endocrine.
[22] P. Chanson,et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. , 2005, The Journal of clinical endocrinology and metabolism.
[23] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[24] M. Chiang,et al. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma , 2005, Journal of Neuro-Oncology.
[25] W. Farrell,et al. Pituitary tumour clonality revisited. , 2004, Frontiers of hormone research.
[26] Luca Regli,et al. Clinical Trial Substantiates the Predictive Value of O-6-Methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastoma Patients Treated with Temozolomide , 2004, Clinical Cancer Research.
[27] Reto Meuli,et al. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] E. Laws,et al. The long-term significance of microscopic dural invasion in 354 patients with pituitary adenomas treated with transsphenoidal surgery. , 2002, Journal of neurosurgery.
[29] E. Laws,et al. Radiosurgery for Cushing's disease after failed transsphenoidal surgery. , 2000, Journal of neurosurgery.
[30] T. Erbas,et al. Radiotherapy in the management of giant pituitary adenomas. , 1999, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[31] J. Herman,et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. , 1999, Cancer research.
[32] A. Norton,et al. Brief, high‐temperature heat denaturation (pressure cooking): A simple and effective method of antigen retrieval for routinely processed tissues , 1994, The Journal of pathology.
[33] M. Cusimano,et al. Pituitary Carcinoma , 1994, Skull base surgery.
[34] C. Matula,et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. , 1993, Neurosurgery.
[35] J. Doppman,et al. Thyrotropin-secreting pituitary carcinoma. , 1993, The Journal of clinical endocrinology and metabolism.
[36] I. MacFarlane,et al. Prolactin secreting pituitary carcinoma. , 1992, Journal of neurology, neurosurgery, and psychiatry.
[37] J. Kaniewska,et al. Cytostatics for acromegaly , 1987 .
[38] M. Davies,et al. PITUITARY CUSHING'S DISEASE ARISING FROM A PREVIOUSLY NON‐FUNCTIONAL CORTICOTROPHIC CHROMOPHOBE ADENOMA , 1985, Clinical endocrinology.
[39] Dale J. Prediger,et al. Coefficient Kappa: Some Uses, Misuses, and Alternatives , 1981 .
[40] S. Hsu,et al. The use of antiavidin antibody and avidin-biotin-peroxidase complex in immunoperoxidase technics. , 1981, American journal of clinical pathology.
[41] C. Marosi,et al. O(6)-methylguanine DNA methyltransferase immunoexpression in nonfunctioning pituitary adenomas: are progressive tumors potential candidates for temozolomide treatment? , 2009, Cancer.
[42] Y. Wang,et al. Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. , 2009, The Journal of clinical endocrinology and metabolism.
[43] K. Kovacs,et al. Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: Morphological findings. , 2007, Human pathology.
[44] A. Verma. MGMT Gene Silencing and Benefit From Temozolomide in GlioblastomaHegi ME, Diserens A-C, Gorlia T, et al (Univ Hosp Lausanne, Switzerland; Univ Hosp Geneva; Swiss Inst for Experimental Cancer Research, Epalinges, Switzerland; et al) N Engl J Med 352:997–1003, 2005§ , 2006 .
[45] J. Kaniewska,et al. Cytostatics for acromegaly. Marked improvement in a patient with an invasive pituitary tumour. , 1987, Acta endocrinologica.
[46] J. Fleiss. Measuring nominal scale agreement among many raters. , 1971 .